This CME program will highlight recent advances in the treatment and management of multiple sclerosis (MS), with a focus on best practices for reducing risk in patients with relapsing forms of MS. The expert faculty will analyze current guidelines and recommendations, highlighting the definitions of MS activity, progression, and worsening. Various emerged and emerging agents for the treatment of multiple sclerosis will be reviewed, and clinical relevance debated. Strategies for individualizing therapy and important clinical considerations for MS treatment and management will be reviewed. Upon completion of this CME program, learners will be better equipped to implement effective, team-based care for multiple sclerosis patients in clinical practice.
Neurologists, primary care physicians, PAs, NPs, and other healthcare providers involved in the management of patients with multiple sclerosis
- Understand the complexity of disease course, treatment sequencing, and remyelination to better treat relapsing forms of multiple sclerosis.
- Examine the most recent advances in therapeutics for the treatment of relapsing forms of MS.
- Apply data-driven evidence into patient-focused treatment strategies to delay disease progression and reduce relapses in patients.
Jerry Wolinsky, MD
Emeritus Professor in Neurology
University of Texas Medical School
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD (Course Chair)||Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma; Receptos, Inc.; Regeneron; Roche; Sanofi; Teva Pharmaceuticals; TG Therapeutics, Inc.
Speaker’s Bureau: Sanofi
|Giancarlo Comi, MD, PhD
|Consultant/Advisor: Actelion Pharmaceuticals; Almirall; Bayer Schering Pharma; Biogen; Celgene Corporation; Genzyme Corporation; Merck; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Pharmaceuticals
Speaker’s Bureau: Actelion Pharmaceuticals; Almirall; Bayer Schering Pharma; Biogen Idec; Celgene Corporation; Genzyme Corporation; Merck; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Pharmaceuticals
|Jerry Wolinsky, MD
|Consultant/Advisor: Alkermes; Brainstorm Cell Therapeutics; EMD Serono, Inc; Genentech Inc.; Genzyme Corporation; GW Pharmaceuticals.; MedDay Pharmaceuticals; NervGen Pharma Corporation; Novartis Pharmaceuticals Corporation; Roche; Sanofi|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Biogen
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].